P
The startup develops a peptide drug that targets the cytokine storm cascade in the lungs to treat and prevent acute lung injury caused by oxygen deprivation. This approach enables healthcare providers to effectively manage lung injury, improving patient outcomes in critical care settings.
Philadelphia, United States
Updated 2 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- The startup develops a peptide drug that targets the cytokine storm cascade in the lungs to treat and prevent acute lung injury caused by oxygen deprivation. This approach enables healthcare providers to effectively manage lung injury, improving patient outcomes in critical care settings.